Tumor News and Research

RSS

Study: Fluorescent probe may serve as useful tool in future surgeries to repair injured nerves

Accidental damage to thin or buried nerves during surgery can have severe consequences, from chronic pain to permanent paralysis. Scientists at the University of California, San Diego School of Medicine may have found a remedy: injectable fluorescent peptides that cause hard-to-see peripheral nerves to glow, alerting surgeons to their location even before the nerves are encountered.

6 Feb 2011

Anti-cancer drug tied to golden missiles

Researchers at Case Western Reserve University have developed a little bomb that promises a big bang for cancer patients.

5 Feb 2011

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

EntreMed, Inc., today announced the publication of key papers on the clinical and preclinical development of ENMD-2076, an Aurora A/angiogenic kinase inhibitor. The clinical data were published in the December 3, 2010 on-line issue of the American Association for Cancer Research journal, Clinical Cancer Research, and are expected to appear soon in the print version of the publication.

4 Feb 2011

Research unmasks long sought stem cell origin of carcinoma

A constellation of different stem cell populations within our skin help it to cope with normal wear and tear. By constantly proliferating, the stem cells allow skin to replenish itself, allowing each cell to be replaced by a new one about once a month. But the normal cycle of division and death within one or more of these stem cell types can sometimes be derailed by genetic mishaps. Such events are believed to spawn carcinomas and other deadly skin cancers, which are the mostly frequently diagnosed cancers in the United States.

4 Feb 2011

New discovery: miR-429 regulatory RNA may be effective in fighting ovarian cancer

Cancer researchers have discovered that a type of regulatory RNA may be effective in fighting ovarian cancer. Ovarian cancer isn't typically discovered until it's in the advanced stages, where it is already spreading to other organs and is very difficult to fight with chemotherapy.

4 Feb 2011

Bayer HealthCare's regorafenib receives orphan drug status for GIST treatment

Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors by the U.S. Food and Drug Administration.

4 Feb 2011

New study provides insight into mechanism behind breast cancer mutation

A new study sheds light on why individuals who inherit a particular family of mutations have a high risk of developing a very aggressive form of breast cancer. The research, published by Cell Press on February 4th in the journal Cell Stem Cell, shows that breast tissue cells from these individuals make abnormal cell-fate decisions even before cancer develops and provides exciting new insights into the mechanisms behind one of the most lethal types of breast cancer.

4 Feb 2011

Scientists unravel mystery about how new tumors in individuals with breast cancer take root

In a discovery that may lead to a new treatment for breast cancer that has spread to the bone, a Princeton University research team has unraveled a mystery about how these tumors take root.

4 Feb 2011

Immune protein exacerbates skin cancer due to sun exposure: Study

An unexpected immune protein exacerbates cancer due to sun exposure, report researchers in the January 27th issue of Nature. The study suggests that drugs blocking the protein might halt tumor growth in skin cancer patients.

3 Feb 2011

Philanthropist awards Mayo Clinic $100 million to establish Proton Beam Therapy Program

Mayo Clinic today announced long-time patient and philanthropist Richard O. Jacobson has given a $100 million gift to help establish the multi-site Mayo Clinic Proton Beam Therapy Program. This is the largest outright gift in the clinic's history, as well as the largest gift Mr. Jacobson has made to any single institution.

3 Feb 2011

Miracle baby after radical new procedure for uterine fibroids

Amy Cordle is the first woman in Australia to become a mother after undergoing a radical new procedure. On Australia Day, the 31-year-old Albert Park woman’s little “miracle” arrived when daughter Neroli was born.

3 Feb 2011

Losartan improves effectiveness of nanotherapeutics against cancer

Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid tumors, improved the effectiveness of two nanotherapeutics against several types of cancer.

3 Feb 2011

Study reveals how MMSET gene enables disease-causing mutations to occur

For several decades, researchers have been linking genetic mutations to diseases ranging from cancer to developmental abnormalities. What hasn't been clear, however, is how the body's genome sustains such destructive glitches in the first place.

3 Feb 2011

Metamark announces Nature journal published landmark prostate cancer study results

Metamark Genetics, Inc., a privately-held oncology molecular diagnostics company, today announced results from a landmark prostate cancer study published as an Advance Online Publication in the journal Nature.

3 Feb 2011

Researchers to develop new diagnostics platform for early detection of lung cancer

The earlier cancers can be detected, the better the chances of a cure. Researchers are now working to develop a new diagnostics platform with which the illness can be diagnosed in its early stages, even during a visit to the general practitioner: protein biomarkers in exhaled air divulge the presence of pathological cells in the lung.

3 Feb 2011

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that the first patient has been enrolled in its Phase II trial of ICT-107 at the New Jersey Neuroscience Institute at JFK Medical Center. ICT-107 is the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

3 Feb 2011

Agilent introduces first commercial RNA target enrichment system

Agilent Technologies, Inc., today introduced SureSelect RNA Capture Kits, the first commercial RNA target enrichment system enabling geneticists to focus on specific genomic loci or transcripts of research interest. The RNA capture kits make it possible to precisely measure expression levels of genes of interest and detect allelic-specific expression, splicing events and gene fusions.

3 Feb 2011

Four-gene/protein signature more accurately predicts metastatic prostate cancer

Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively, researchers at Dana-Farber Cancer Institute report in a study published online today by the journal Nature. The discovery lays the groundwork for the first gene-based test for determining whether a man's prostate cancer is likely to remain dormant within the prostate gland, or spread lethally to other parts of the body.

3 Feb 2011

Scientists challenged to sequence genome and RNA content derived from single cancer cell

Life Technologies Corporation today announced that the Life Grand Challenges Contest, initially introduced in December 2010, is expanding to include a fourth challenge. This latest contest challenges scientists to sequence the genome and all RNA content derived from a single cancer cell using the 5500 Series SOLiD™ Sequencers.

3 Feb 2011

EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer

EGEN, Inc. today announced that the Food and Drug Administration (FDA) has awarded the company a four-year grant of $1,600,000 to assist in the Phase II clinical development of EGEN-001, the company's lead product. EGEN-001 is under clinical development for the treatment of advanced recurrent ovarian cancer.

2 Feb 2011

Tumor News and Research

Study: Fluorescent probe may serve as useful tool in future surgeries to repair injured nerves

Anti-cancer drug tied to golden missiles

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

Research unmasks long sought stem cell origin of carcinoma

New discovery: miR-429 regulatory RNA may be effective in fighting ovarian cancer

Bayer HealthCare's regorafenib receives orphan drug status for GIST treatment

New study provides insight into mechanism behind breast cancer mutation

Scientists unravel mystery about how new tumors in individuals with breast cancer take root

Immune protein exacerbates skin cancer due to sun exposure: Study

Philanthropist awards Mayo Clinic $100 million to establish Proton Beam Therapy Program

Miracle baby after radical new procedure for uterine fibroids

Losartan improves effectiveness of nanotherapeutics against cancer

Study reveals how MMSET gene enables disease-causing mutations to occur

Metamark announces Nature journal published landmark prostate cancer study results

Researchers to develop new diagnostics platform for early detection of lung cancer

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

Agilent introduces first commercial RNA target enrichment system

Four-gene/protein signature more accurately predicts metastatic prostate cancer

Scientists challenged to sequence genome and RNA content derived from single cancer cell

EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News